November 19, 2026
Read time: ~5 minutes.
Hepatitis C rarely announces itself. Many people live with the infection for years without symptoms, allowing the virus to damaged the liver before the infection is discovered.
The Centers for Disease Control and Prevention (CDC) estimates more than 2 million people in the United States have hepatitis C, and up to 1 million remain unaware of their infection. Despite the number of undiagnosed cases, hepatitis C is curable. Short-course antiviral treatment lasting 8 to 12 weeks cures more than 95% of infections, according to the World Health Organization (WHO).
Test plays a critical role in closing the gap between an effective cure and the number of people who actually receive treatment.
Hepatitis C Is Curable, but Most People Aren’t Cured
A CDC analysis of laboratory data from 2013 to 2022 found that only about 1 in 3 people with evidence of current infection later showed evidence of viral clearance. Clearance rates are even lower among people without health insurance, people with Medicaid, and adults under 40, the group with the highest rates of new infections.
A 2024 state-by-state CDC report found a median clearance rate of 29%, with rate ranging from 10% in West Virginia to 51% in Connecticut. National goals call for at least 58% of people with hepatitis C to achieve viral clearance by 2025 and 80% by 2030.
Where Patients Fall Out of the Testing Pathway
Standard hepatitis C diagnosis typically takes two steps. An initial antibody test identifies whether a person has ever been exposed to the virus. A reactive result requires a follow-up RNA test to determine if the infection is current. In many healthcare settings, providers schedule these tests on different days and send samples to an outside laboratory for analysis.
Each additiona appointment creates an opportunity for a patient to drop out of care. That risk is highest for people who move frequently, lack reliable transportation, or receive care through emergency departments, syringe service programs, or correctional facilities. A March 2026 economic analysis in JAMA Network Open found the standard lab-based approach is associated with high rates of undiagnosed cases, loss to follow-up, and low treatment initiation, particularly among high-risk populations.
Point-of-Care Testing Shortens the Path to Treatment
Point-of-care testing brings the results directly to the patient during the same visit. In June 2024, the U.S. Food and Drug Administration (FDA) authorized the first point-of-care hepatitis C RNA test for use in settings with a Clinical Laboratory Improvement Amendments (CLIA) Certificate of Waiver. Providers can use testing to confirm current infection and begin linking a patient to care in one encounter.
The same JAMA Network Open study modeled an RNA-first point-of-care strategy across community health centers, emergency departments, harm reduction clinics, and mobile outreach programs. Compared with standard lab testing, the strategy increased linkage to care by 37.6% – 73.4% and treatment initiation by 12.1% – 48.9%. Overall costs also decreased in every setting analyzed.
Public health programs are already incorporating point-of-care testing into practice. New York State’s 2026 hepatitis C elimination progress report highlights point-of-care diagnostic testing in all 12 of the state’s drug user health hubs, with fingerstick collection and diagnosis within one hour.
The Global Picture Ahead of 2030
The global challenge extends well beyond the United States. WHO’s 2026 Global Hepatitis Report recorded 0.9 million new hepatitis C infections and an estimated 240,000 hepatitis C deaths in 2024. Since the introduction of widely available 12-week curative treatment in 2015, only 20% of people with hepatitis C have received treatment.
People who inject drugs accounted for 44% of new infections. WHO is urging countries to integrate hepatitis testing and treatment into primary care to reach affected communities where they already receive services. Expanding access to these communities requires testing solutions that function outside traditional laboratory settings.
The Importance of Rapid Antibody Screening
Although point-of-care RNA testing gets much of the attention, identifying people with prior exposure remains the first step in many screening programs. Rapid antibody tests offer a practical screening option for clinics, outreach programs, and international healthcare systems. These test do not require a instrumentation, many work with fingerstick whole blood samples, and results are rapid, while the patient is still present.
A rapid antibody screening does not provide a standalone diagnosis of current infection. Antibodies can remain detectable after an infection clears naturally or following successful treatment. Consequently, a reactive antibody result requires follow-up RNA testing to confirm whether the infection is current. When the antibody screen and the confirmatory step are coordinated, ideally during the same visit, fewer patients are lost for follow-up.
Healgen Supporting Hepatitis C Elimination
The Healgen HCV test is a lateral flow immunoassay that qualitatively detects anti-HCV antibodies (IgG, IgM, and IgA) for use as a screening test and an aid in diagnosis. Available in strip and cassette formats, the test is able to use whole blood, serum, and plasma, which allows programs flexibility in their collection methods. Storage at room temperature or refrigerated (2–30°C) also helps outreach programs and clinics without dedicated cold storage.
Programs that screen for multiple blood-borne infections can also use the Healgen HBsAg/HCV Combo test, which is able to detect hepatitis B surface antigen and hepatitis C antibodies from one sample. The Healgen HBsAg/HCV/HIV/Syphilis Combo test screens for four infections from a single sample. Combination testing supports WHO’s initiative to integrate hepatitis screening into routine healthcare rather than managing each infection as separate programs.
Turning Awareness into Action
For distributors and purchasing teams, expanding elimination programs, harm reduction networks, and correctional health services creates opportunities to increase testing. Simple, rapid antibody tests, with room storage, offer practical advantages for these programs and their supply chains.
For clinics, community health centers, and outreach programs, pairing rapid antibody screening with an RNA confirmation pathway reduces the number of patients lost between testing steps. Planning the testing pathway before screening begins helps ensure a reactive result from turning into a missed diagnosis and lost care.
For individuals, the CDC recommends that every adult get tested for hepatitis C at least once, with routine testing for people with ongoing risk factors. Early detection provides an opportunity to access treatment and is the first step toward being cured.
If your organization is building or expanding a hepatitis C screening program, contact us online to learn more about Healgen’s blood-borne infectious disease portfolio.
This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. The Healgen HCV test, HBsAg/HCV Combo test, and HBsAg/HCV/HIV/Syphilis Combo test are not available for sale in the United States. For availability in the EU and other countries, please contact Healgen.

